return equiti ttm
strong pipelin catalyst leav us encourag sustain impella
near-term uncertainti believ long-term investor keep build posit
level given steadi stream catalyst uniqu clinic valid technolog
strong margin profil under-penetrated market
ahead next week analyst day publish deep dive look product
clinic pipelin main focu point head next week believ
outlook becom posit driven healthi stream pipelin catalyst
earli sign stabil underli busi also walk could
mean earn perspect five-year financi scenario analysi despit
share trade well high well
peak valuat time ntm sale versu time peak follow period
deceler growth recal growth start deceler follow impella rp
warn letter februari ultim rp safeti efficaci re-affirmed though
letter expos underli issu around train product/market
develop effort need support adopt within next group physician
stock start rebound somewhat compani four five quarter
reinvest process expand matur salesforc increas physician train
effort roadmap
pandem neg impact procedur chang timelin
next-gen product even acceler adopt remot
interfac technolog thu head next week analyst day feel increasingli
comfort regalvan team execut initi
compani near sustain reacceler point coupl compani
under-penetrated market opportun uniqu technolog believ share
attract long-term investor
improv eas use drive impella adopt util five-plu year
growth reach next leg physician adopt curv mani
next clinician adopt less comfort larg bore access
address need product innov start earli increas
educ invest help train new physician drive deeper account penetr
new rep typic take month becom product full benefit
effort yet seen product front launch impella late
offer physician better axillari access potenti easier implant ambul
shock patient also highlight on-going roll-out smartassist impella connect
provid advanc softwar hospit connect servic streamlin patient
make number cardiac-assist devic treat acut heart failur compani portfolio
highlight impella product first percutan catheter-bas cardiac assist devic
summari key catalyst
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
look forward next catalyst improv eas use launch expand sheath allow impella
cp implant greater smaller diamet access site expect end calendar year earli
respect manag believ bring addit physician sidelin particularli
uncomfort larg bore access lastli perhap meaning compani ecp pump expect
deliv similar flow rate cp true french design smaller cp full ecp launch still month
away recent updat earli trial start calendar ahead expect
meaning expans provid anoth tailwind growth potenti meaning expans front
highlight on-going though current paus due stemi trial open increment billion
domest market opportun importantli trial design size rigor need chang standard care
outcom posit even enrol mileston trial could prove stock catalyst secondli compani
impella btr product design address increment billion market opportun btr develop like take
year long-term potenti expans lastli expect detail recent breeth ecmo
acquisit open new market opportun also potenti synergist impella sale
clinic trial chang societi guidelin asid on-going stemi trial manag outlin revamp
clinic map aim achiev class societi guidelin use impella hrpci cardiogen shock detail
time protect iv hrpci recov iv shock trial still somewhat light expect detail next week
know aim chang standard care
conclus stock thought
near-term result neg affect encourag underli momentum
demonstr earli benefit recent commerci clinic effort reacceler growth came
away fourth-quart call encourag manag dedic long-term growth initi
thought materi posit updat clinic larg track pipelin expand time ecp
ahead schedul initi taken togeth believ well posit emerg
environ matur commerci initi expand matur salesforc bolster clinic back
aim class recommend support sustain acceler growth larg under-penetrated market
clinic valid solut share trade time calendar revenu estim million
growth rate stock outperform
focu point next week analyst meet
product updat highlight note meaning enough drive next leg adopt among
physician improv access closur meaning sidelin
upcom clinic trial properli design appropri size design endpoint convinc even
never impella physician adopt impella hrpci cardiogen shock
implic long-term market trend posit potenti chang market
smartassist impella connect pipelin virtual solut chang perman
abiom need want addit product round mechan circular support portfolio beyond
recent acquir breeth machin ecmo
kind market develop effort clinic trial need develop ecpella ecmo plu impella
market distract rep current hrpci/shock effort expand headcount
long-term sale growth margin outlook specif lever achiev
discuss pipelin detail
impella solidifi leadership offer tailwind shock growth impella offer sever improv
predecessor impella believ offer broad tailwind adopt util within cardiogen
shock opportun system complet overhaul increas flow rate l/min design
tweak easier implant axillari access noteworthi updat eas use potenti even improv patient
provid in-depth discuss impella enhanc expect help continu
momentum under-penetrated less billion domest shock opportun
axillari access support better patient recoveri impella design specif axillari access rather
tradit femor access support better patient mobil extend recoveri period easier
mobil patient shoulder access rather groin access still receiv full hemodynam support
l/min today impella physician heavili reli axillari access alreadi offer
shorter rigid pump cannula allow greater flexibl curv axillari arteri ultim support
easier placement pump altogeth design axillari access potenti improv
physician comfort place impella also improv patient outcom nativ heart recoveri allow
patient mobil recoveri period
increas flow rate provid near full hemodynam support pump provid liters/minut blood
flow liters/minut impella time greater liter/minut provid
tradit iabp nativ cardiac flow rate vari person liters/minut flow high end
nativ heart pump impli impella provid shock patient nearli full hemodynam
design extend wear time extend wear time key featur devic shock popul given
sever diseas need long period hemodynam support extend day sometim
even week post-procedur dr bernhardt univers heart center germani one first user impella
suggest greater cardiogen shock patient hospit stay longer day
emphas need reliabl power safe long-last impella offer sever design chang
improv perform higher flow rate reliabl less complic use extend period
includ tweak pump design better axillari access enabl better patient mobil icu
subsequ could improv long-term outcom new pump also offer redesign compani pigtail
essenti elimin pigtail potenti reduc complic concern complic
associ blood clot pigtail extend use also note impella indic
day use unit state europ respect believ uniqu posit market
iabp intend use day extend support lastli size pump
reduc french smaller french diamet support better
patient outcom less access closur complic increas physician comfort use devic
smartassist support better nativ heart recoveri impella includ compani latest optic sensor
detail later note allow physician use advanc featur new smartassist consol
note provid physician real-tim nativ cardiac output even patient impella support
allow care wean patient impella restor nativ heart power increas
physician hospit staff comfort use impella devic also potenti improv outcom
prevent earli loss support
expect noteworthi upgrad reinforc even extend impella leadership posit within
cardiogen shock on-going launch impella abl support compani momentum shock
drive adopt among physician previous uncomfort access axillari design smaller size
manag smartassist support util physician look better support shock patient pump
receiv ce mark april receiv fda approv septemb current limit market releas
site fiscal fourth-quart call manag highlight continu posit feedback continu
believ impella act broad tailwind adopt cariogen shock key growth driver
compani especi industri nois hrpci neg impact segment
access closur address expand sheath expand sheath allow impella
cp implant french access cathet offer nearli reduct cathet size current french
help address concern larg bore access closur among next like group impella adopt
manag point lack comfort case skill larg bore access closur key factor
recent growth deceler especi within hrpci launch expend sheath meaning
catalyst impella growth physician becom comfort use
new sheath design temporarili expand impella pass deliveri system return reduc
profil devic pass allow cardiologist use smaller access site implant devic even
implant devic larger bore requir unexpand sheath technolog use
deliveri tavr valv nearli year exampl edwardss ew outperform first expand sheath
introduc today french expand sheath use deliv french tavr valv contribut
improv clinic outcom especi surround access closur complic
edward lifesci compani presentationexampl expand sheath tavrunexpandedexpandedreduc profil william blair
acknowledg improv tavr outcom last decad attribut numer factor
highlight vastli improv access complic rate edwardss trial believ demonstr
clinic potenti expand sheath specif clinic trial use
french sheath show approxim rate major vascular complic decreas vascular
complic rate low recent trial use smaller profil devic compani
french expand sheath believ clear clinic benefit patient also believ launch
smaller access devic provid broad tailwind market adopt year expect someth similar happen
impella
despit headwind medic devic compani pipelin expand sheath timelin larg
track slightli ahead expect anticip clearanc file fiscal second quarter septemb
impella expand sheath manag guid file impella expand sheath
shortli fda normal review period submiss suggest sheath could
market calendar year-end shortli follow cp devic alreadi use new sheath
hand patient august highlight posit anecdot feedback date overal feel comfort
timelin believ expand sheath could prove catalyst impella util
well paradigm-shift impella ecp devic impella ecp expand cardiac power
develop year opinion repres next major breakthrough offer similar flow rate
impella cp liters/minut true french pump design smaller access site cp put anoth way ecp
provid physician three four time flow rate iabp mention superior lv unload characterist
associ impella compar size access tradit iabp develop launch ecp could
one meaning pipelin product catalyst near term drive long-term adopt util primarili
hrpci lesser degre within cardiogen shock less penetr billion hrpci market ecp
act meaning catalyst growth
impella ecp pump part abiom effort sinc origin acquir impella cardiosystem
bolster acquisit entwicklungsgesellschaft mbh uniqu form factor function made
possibl use expand pump shaft motor power deliv outsid bodi rather insid
pump/cathet design allow ecp insert aortic valv pump deflat henc smaller gaug
size expand fr support high flow rate place insid heart/aorta
pump expand polyurethan membran creat outflow cannula divert blood left ventricl
aorta compar rigid nitinol cannula use impella devic design obviou benefit
expand also expect less traumat soft tissu contact help prevent blood regurgit shut
pump ecp motor outsid bodi manag expect system simpl use work
seamlessli current impella pump base
despit nearli decad develop ecp pump like still year away broad market releas said
recent updat manag encourag meaning execut product develop on-going
discuss fda clinic pathway unit state potenti even acceler pathway abiom
note commerci product alreadi complet first-in-man usag plan april time frame
prevent team travel procedur call
regardless move forward ecp alreadi file approv feasibl trial fda
manag believ potenti acceler pathway unit state earli indic leverag
center physician particip feasibl trial roll pivot trial outcom posit
manag believ potenti ecp pivot trial requir multi-year outcom instead
design single-arm studi focus safeti efficaci devic versu protect ii protect trial overal
compani progress commerci product coupl potenti abil roll trial particip run
rel shorten trial compar multi-year put ecp meaning ahead origin expect
commerci launch expect get detail timelin manag next week analyst day
improv access closur mean growth previous discuss manag identifi
cohort target physician use impella greatli underutil impella part due concern larg
bore cathet complic admittedli difficult put exact number mani doctor fall within
categori think annual iabp market good corollari potenti opportun sinc case
physician see need alreadi use support devic albeit smaller access use
believ clinic inferior product
estim approxim iabp still use annual unit state compar estim
approxim impella pump use fiscal iabp market repres billion
addit domest market opportun assum asp among physician alreadi use arguabl
clinic inferior product note also highlight ecmo procedur perform annual
potenti opportun larg focu iabp market sinc ecmo usual use cardiac arrest patient need
hemodynam oxygen support impella oxygen blood follow acquisit breeth
develop next-gen ecmo devic compani meaning compet ecmo market access
closur improv gear market sum estim everi basi point iabp share
abl captur add million annual sale nearli basi point increment growth full year
breeth acquisit expand market ecmo offer potenti synergi recent announc
acquisit breeth portabl ecmo machin complement portfolio product aim support patient
ambul ultim nativ heart recoveri manag highlight system portabl eas use
competit differenti current ecmo devic could potenti enabl market share gain exist
annual domest case opportun perhap even meaning potenti synergist impella sale
perform ecpella case ecmo use oxygen blood impella use unload left ventricl support
end organ manag estim approxim ecmo case could benefit impella use could provid
tailwind adoption/util time
said includ revenu contribut breeth fiscal estim either devic
impella pull-through wait clearanc initi traction compani limit releas fiscal fourth
quarter earli calendar believ acquisit help round mechan circulatori support
portfolio system aim nativ heart recoveri wait meaning execut increas estim
head next week analyst day focus breeth system competit advantag potenti
steal market share well clinic data public ecpella capabl deliv pull-through impella
date breeth clinic user top physician suggest could strong initi
traction within account
impella bridg recoveri btr open new market uniqu solut still long-term product impella btr
first impella pump intend outpati use provid treatment altern certain late-stag heart failur
patient escal invas therapi line compani long-stand mission abiom
believ unload heart help patient return baselin heart function avoid escal treatment improv
outcom lower cost btr leverag compani core impella technolog new devic intend
entir new patient popul expect expand address market increment billion
annual patient
specif target class heart failur patient worsen condit despit medic manag
hope unload patient heart allow nativ heart recov avoid perman invas
treatment like lvad heart transplant result btr meaning compet current lvad system
larg indic class iv heart failur extrem class case sinc focus help patient
return baselin heart function
system expect purgeless fulli implant motor built pump control small
extern control rather tradit in-hospit control unit use today purgeless design incorpor
mobil control two main featur enabl patient leav hospit still receiv circulatori
support impella btr note mobil control also provid caregiv real-tim cardiac data
pump optic sensor allow better patient monitor patient hospit effici wean
devic
provid much guidanc term impella btr mileston either develop regulatori
believ compani still earli stage develop system said manag recent note
develop launch impella would lay groundwork btr devic given shorter cannula curv
neck allow perman placement aortic valv expect meaning updat btr
upcom analyst meet believ potenti expand compani even also note
look essenti creat new market circulatori support medic manag patient
like need larg well-run random control trial chang societi guidelin secur reimburs prove
benefit devic educ clinician step like take time meaning effort
look expand new market opportun
impella servic support util impella lower barrier adopt
smartassist smartassist next-gen softwar platform control unit potenti improv
adopt util impella provid real-tim action cardiac output data lower burden impella
use believ smartassist increment support impella growth improv physician confid use devic
help ensur proper placement/wean could ultim lead improv util adopt pump
fact manag note pickup pump util account fulli convert smartassist
believ incorpor smartassist softwar prove import pandem
hospit look solut digit manag patient limit interact need roll-out still
somewhat earli believ feedback demonstr potenti streamlin care support broader impella
util highlight notabl featur smartassist platform
nativ cardiac output wean algorithm use read optic sensor axial motor smartassist
abl display sever new measur patient real-tim nativ cardiac power output left ventricular
end-diastol pressur mean arteri pressur real-tim data display impella consol
connect monitor devic like comput tablet provid physician valuabl tool
wean patient impella pump ensur adequ heart recoveri process believ
advanc extend valu user potenti improv outcom physician better
wean patient extend lead potenti futur competit
easier reposit smartassist platform physician abl reposit impella pump
elimin need cath lab ultrasound imag specif physician abl use real-tim aortic
pressur left ventricl read ensur pump properli place without leav icu expect
increment benefit help improv util adopt impella pump becom easier
potenti less costli manag less imag fewer cat lab visit
impella sheathimpella ecpimpella btrtime launch underwayl earli trial cy year wb estim target market exist cardiogen shockhrpci cardiogen shockexist hrpciclass heart failuretarget market exist patientsexist marketsexist patientsnew patientstarget market billion billionfisc share fr fr liter per minutenaup liter per minuteup liter per minutenot featur longer wear time day increas flow rate l/min improv axillari access- decreas lt use complications- expand sheath impella follow impella cp shortli after- reduc access profil impella- fr pump size smallest offer expand soft membran pump- similar flow rate cp l/min rate similar l/min lt use year patient discharg home- plugless designsourc william blair estimatessummari notabl pipelin product william blair
reduc set-up time smartassist design enhanc user interfac streamlin impella consol set
turn streamlin usag pump lower burden associ use believ
new platform set second
smartassist enter limit launch middl calendar fiscal fourth quarter call
use site impella procedur roll-out smartassist degre
acceler desir hospit remot manag patient especi use tie impella
connect expect critic part impella usag go forward impella cp current
devic compat smartassist manag expect futur product launch compat new
softwar well
impella connect impella connect cloud-bas hipaa-compli remot monitor system allow physician
view screen impella consol real-tim comput mobil smart-devic caretak
use connect monitor patient also offer day per week monitor servic
compani new clinic support center monitor patient alert hospit patient need attent
exampl clinic support center abl monitor real-tim smartassist data alert hospit patient
impella pump need reposit rep also call caretak guid
impella connect part made possibl introduct smartassist though connect expect entir
separ service/product sold account provid increment revenu stream long run meantim
effort expedit evolut digit manag roll remot
monitor aspect impella connect account smartassist free charg expect patient monitor servic
new revenu stream develop time potenti meaning updat next week analyst
sum think impella connect help break barrier physician comfort use impella pump even
support staff may untrain watch patient overnight time doctor call allow
physician better alloc effici time well bring attent alarm perhap
silenc near term believ connect offer effici potenti clinic benefit allow
gather trove data clinic econom support long-term train util impella devic
abiomedimpella screen consol smartassistreal-timen cardiac output monitor properli wean patient pump support doctor see nativ output increas decreas pump flow william blair
stemi stemi life-threaten heart attack one heart main arteri becom nearli
complet block prevent blood reach heart estim individu experi stemi heart
attack everi year repres billion annual treatment market stemi requir rapid reperfus
arteri restor blood flow prevent long-term complic death hospit stemi uniqu identifi
ecg show abnorm st section patient heart wave henc name st-elev mi
abnorm st section ecg usual indic larg portion heart muscl risk especi
compar non-stemi patient note increment stemi market opportun patient cardiogen
shock impella alreadi label treat stemi patient cardiogen shock
industri focu stemi patient reduc mortal rate last decad recent registri data suggest low
five year estim stemi survivor becom heart failur patient within five year
treatment emphas need improv outcom beyond mortal result pivot trial stemi
effort acut focus reduc infarct size size dead heart muscl post-stemi treatment
believ promot better nativ heart recoveri subsequ lower heart failur
fact sever data set support thesi patient-level analysi randomized-control stemi
trial total patient sort patient quartil base infarct size ultim found signific
reduct one-year mortal heart-failur hospit patient smaller infarct size result abiom
pivot trial also focus reduc infarct size stemi patient hope improv long-term mortal re-
better understand role impella play improv stemi outcom work ahead creat
market import understand year industri effort improv treatment protocol subsequ
guidelin creat stemi treatment
decreas time reperfus current gold standard stemi unsurprisingli clinic data demonstr
neg relationship amount time arteri block heart attack severity/odd surviv
result cardiologist emphas idea time muscl look unblock arteri quickli possibl
minim door-to-balloon time aha guidelin specif state stemi patient receiv pci
within minut admit hospit improv outcom decreas mortal aha
start allianc goal help increas percentag stemi patient receiv pci less
minut despit success reduc time stemi patient long-
term clinic outcom demonstr need better nativ heart recoveri previous highlight
impella come unload heart reperfus reduc infarct size believ use
impella stemi patient without cardiogen shock reduc infarct size subsequ improv clinic
outcom less heart failur impella use stemi uniqu call cardiologist wait minut
open block arteriesa concept goe directli current industri standard theori
unload heart minut reduc strain heart ultim reduc infarct size improv
nativ heart recoveri result even impella gain approv stemi patient like need
revamp hospit physician think heart recoveri patient popul specif
design stemi pivot trial size endpoint way believ provid strong clinic case delay
reperfus detail indic approv fda alreadi data need
chang standard care
stemi pivot trial underway stemi pivot trial start enrol decemb though enrol
paus due line delay seen med-tech peer accord clinicaltri gov roughli
patient enrol trial paus though expect speed enrol somewhat acceler
site come on-line last public updat manag gave site activ site activ
ramp new particip
patient random either standard careimmedi reperfus circulatori supportor delay
reperfus minut unload impella cp note control arm pivot trial differ
safeti feasibl trial discuss detail safeti feasibl studi impella-support delay
reperfus arm compar immedi perfus arm also receiv circulatori support impella
primari endpoint pivot trial infarct size percent left ventricular mass three five day
reperfus though manag intend follow patient long six year better understand long-term outcom
two group difficulti enrol past patient want consent
potenti receiv impella manag reiter confid enrol stemi trial given novel use
posit experi safeti feasibl trial site site also pivot trial
enrol complet manag believ abl file fda within six month overal believ stemi
approv like two three year away remain import long-term growth driver potenti
doubl address market
stemi safeti feasibl trial pave way pivot novemb announc posit result
stemi safeti feasibl trial left manag confid move forward pivot trial safeti
feasibl studi rct assess outcom two impella-support arm first arm receiv pci
immedi current standard care plu impella support second arm unload impella cp
minut prior pci procedur half patient enrol receiv immedi reperfus ir half
receiv reperfus minut unload ur impella cp mean time immedi delay
reperfus group minut respect one hundr percent patient arm complet treatment
protocol support safeti feasibl unload stemi patient reperfus
primari safeti outcom composit macc event includ cardiovascular mortal reinfarct
stroke major vascular event day differ macc rate two group
statist signific macc rate ir ur patient respect
secondari outcom includ patient myocardi salvag index day infarct size day
differ level statist signific two group overal level
infarct size also significantli differ infarct size ir ur group
note patient st-elev sum mm patient largest portion heart muscl risk
experienc statist significantli higher rate ur group vs especi
encourag consid safeti feasibl trial design show superior immedi reperfus
stemi hypothesi also support variou anim trial manag highlight sever publish anim trial
demonstr benefit unload impella reperfus data demonstr unload
minut reperfus much smaller benefit decreas infarct size data
combin compani decad knowledg experi circulatori support led
unload period test stemi pivot trial
 vascular unload dtu stemi safeti feasibl pilot trialurirmajor advers cardiac cerebrovascular event william blair
revamp rct effort open possibl class societi recommend
recent establish definit roadmap upcom clinic trial focu rigor
capabl chang standard care receiv class guidelin recommend trial focus
compani two main exist opportun hrpci cardiogen shock well market expand opportun
previous discuss stemi trial
arguabl extens clinic support impella today rct data consid gold standard
cardiolog limit less clear physician would like end willing execut
run sever impella rct meaning event sinc potenti convert clinicians/increas user
util also chang societi guidelin standard care addit detail new trial beyond
alreadi discuss stemi market/pivot expect manag provid detail around trial design
timelin next week investor day
protect iv hrpci believ protect iv next trial start enrol expect start within next
year build hrpci treatment protocol fine-tun protect random patient
either impella support plan mechan circulatori support manag specif focus
hrpci patient receiv sinc larger market opportun potenti even harder
popul given complic iabp
hrpci oldest indic make approxim total sale said
weakest segment compani past sever quarter believ due rel softer benefit
especi compar shock rehospit versu mortal need extens hub spoke
network refer patient impella capabl center believ well-run rct trial act meaning catalyst
help front expect get detail surround size endpoint protect iv
recov iv shock lastli plan run rct within cardiogen shock recov iv leverag mani
center enrol stemi trial mean time somewhat depend progress stemi
onboard train result time least certain recov iv note shock continu rel
strong momentum growth third quarter growth demonstr less need
sustain segment growth expect on-going trials/registri like danger trial shock rct
denmark nation cardiogen shock initi support growth eventu readout recov
iv trial could chang guidelin provid posit inflect shock growth futur
abiom compani presentationth rational dtu pilot pivot trialanim trial resutl william blair
compani last host analyst day manag provid five-year outlook guidanc around
revenu oper margin unlik hit fiscal revenu target though alreadi seen oper
margin expect given near-term uncertainti caus expect manag
provid formal long-term outlook next week meet though could potenti discuss high-level growth
margin expect would focus manag comment around old guidanc rang work
didnt believ continu deliv industry-lead growth margin profil
ultim believ manag view compani double-digit midteen grower publish street number
right impli similar rang fiscal achiev though well compani support
growth trajectori key question stock mention believ robust product pipelin
upcom invest clinic data expand reacceler growth trajectori manag also
spoken drive industry-lead oper margin suggest potenti oper margin expans
though would expect back end long-term rang versu front end time horizon
includ potenti scenario around metric manag choos provid guidanc revenu
estim assum growth fiscal five year come midteen impli sale billion
low end assum high-single-digit growth high end assum growth number input
estim though would assum roughli penetr hrpci shock versu today
includ revenu impella connect impella ecp stemi indic may conserv
 statement perspect gross margin alreadi one highest medic technolog give
compani substanti flexibl invest area busi deliv respect margin comparison
edward lifesci deliv oper margin revenu rate billion though sg percent sale
versu fiscal around sale
short term continu invest market develop train effort accordingli believ
compani dedic meaning resourc effort educ physician build impella program
throughout countri effort like requir sustain sg expens near term sale
said believ compani abl show leverag sg go forward scale awar
believ like stay rel stabl current level given number pipelin indic product
compani pursu may see acceler growth compani launch next-gener
said key growth engin futur area expect manag continu invest
william blair co estim repres wb estim illustr purpos onlyabiom target william blair
risk abiom growth heavili depend continu increas adopt util singl product
impella compani unabl suffici demonstr clinic econom benefit impella growth
neg impact physician curtail use pump near term compani must also refut recent
present data suggest poor outcom impella devic potenti slow growth impella use
long term clinic data collect remain import compani also like need execut pipelin
product capabl support widespread use pump delay inabl execut pipelin product
need regulatori approv well limit long-term growth
william blair co estim assum share count million tax rate mil ep scenariosoper margin import disclosur
